Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2012
04/03/2012US8148343 Tumor suppressor factor
04/03/2012US8148320 Peptide inhibitors of ABL kinases
04/03/2012US8148125 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
04/03/2012US8148114 Materials and methods for treatment of inflammatory and cell proliferation disorders
04/03/2012US8148080 Gene and protein relating to hepatocellular carcinoma and methods of use thereof
04/03/2012CA2617725C Novel cysteine protease inhibitors and their therapeutic applications
04/03/2012CA2613015C Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
04/03/2012CA2501690C Amended recombinant cells (arcs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants
04/03/2012CA2432792C Methods for modulating tumor growth and metastasis
04/03/2012CA2423744C Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
04/03/2012CA2294981C Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
04/01/2012CA2716264A1 Use of ganglioside to decrease propagation of malignant prostate cells
03/2012
03/29/2012WO2012040623A2 Nanostructured gels capable of controlled release of encapsulated agents
03/29/2012WO2012040587A2 Compositions and methods for altering matrix rigidity to regulate cancer cell growth and phenotype
03/29/2012WO2012040527A2 Deubiquitinase inhibitors and methods for use of the same
03/29/2012WO2012040492A1 Methods of treating cancer comprising targeting nqo1
03/29/2012WO2012040331A2 Multistage nanoparticles
03/29/2012WO2012040323A2 Multimeric il-15 soluble fusion molecules and methods of making and using same
03/29/2012WO2012040126A1 Substituted nucleotide analogs
03/29/2012WO2012040095A1 Qsox1 as an anti-neoplastic drug target
03/29/2012WO2012039908A2 Method and compound for treatment of cancer using phosphorous-32 labeled dna
03/29/2012WO2012039855A1 Ph-sensitive compositions for delivery of beta lapachone and methods of use
03/29/2012WO2012039793A1 Methods and compositions for treating lung cancer
03/29/2012WO2012039460A1 Substituted amide compound
03/29/2012WO2012039197A1 Agent for enhancing trail sensitivity
03/29/2012WO2012038965A1 Dietary supplement containing morinda citrifolia (known as noni) powder and preparing method thereof
03/29/2012WO2012038944A1 Matrix metalloproteinase inhibitors
03/29/2012WO2012038943A1 Matrix metalloproteinase inhibitors
03/29/2012WO2012038905A1 Thienopyridine nicotinamide derivatives, preparation thereof and therapeutic use thereof
03/29/2012WO2012038904A1 Nicotinamide derivatives, preparation thereof and therapeutic use thereof
03/29/2012WO2012038743A1 Pyrazolopyridines as inhibitors of the kinase lrrk2
03/29/2012WO2012038694A1 Anti-cancer compounds
03/29/2012WO2012038605A1 Viral therapy enhancing adjuvant
03/29/2012WO2012038590A1 Improved dietary substitution for treating or preventing cancer
03/29/2012WO2012038504A2 Breast cancer therapeutics
03/29/2012WO2012038417A1 Substituted amino - benzoic acid derivatives as inhibitors of dna methyltransferases
03/29/2012WO2012038307A1 Spiro substituted pyrrolo[1,2-c]imidazole derivatives useful as mdm2 inhibitors
03/29/2012WO2012037687A1 Therapeutic polypeptides and uses thereof
03/29/2012WO2012037616A1 Interferon-nu
03/29/2012WO2012018145A3 Agent for improving quality of life
03/29/2012WO2012013282A8 Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
03/29/2012WO2012003563A4 Antineoplastic pharmaceutical compositions containing substituted nitroaromatic compounds
03/29/2012WO2012003562A4 Antineoplastic pharmaceutical compositions containing substituted nitroimidazoles
03/29/2012WO2012001065A3 Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
03/29/2012WO2011163198A3 Tg2 inhibitors and uses thereof
03/29/2012WO2011153485A3 Use of the sparc microenvironment signature in the treatment of cancer
03/29/2012WO2011143579A9 Cancer prevention and treatment methods based on dietary polyamine content
03/29/2012WO2011140527A3 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
03/29/2012WO2011140519A3 In vivo gelling pharmaceutical pre-formulation
03/29/2012WO2011140517A9 Methods for treating diseases of the lung
03/29/2012WO2011140267A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
03/29/2012WO2011140132A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
03/29/2012WO2011139907A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
03/29/2012WO2011139801A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
03/29/2012WO2011139791A3 Bisphosphonamidate prodrugs and uses thereof
03/29/2012WO2011133879A3 Combination therapies with mitochondrial-targeted anti-tumor agents
03/29/2012WO2011133827A3 Method of treating prostate cancer
03/29/2012WO2011131925A3 Osmium (ii) arene azo anti-cancer complexes
03/29/2012WO2011123524A3 Macrolide inhibitors of mtor
03/29/2012WO2011120327A9 Anti-tumor medicament of structure of diarylurea or thiourea kind based on indazole or aza-indazole
03/29/2012WO2011112935A3 Antibody fusion proteins with disrupted heparin-binding activity
03/29/2012US20120078028 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
03/29/2012US20120077985 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
03/29/2012US20120077876 Method For Improved Bioactivation Of Pharmaceuticals
03/29/2012US20120077871 9, 10-Alpha, Alpha-OH-Taxane Analogs and Methods for Production Thereof
03/29/2012US20120077867 Compositions And Methods For Treating Pancreatic Cancer
03/29/2012US20120077866 Antisense modulation of c-reactive protein expression
03/29/2012US20120077862 Antisense modulation of ptp1b expression
03/29/2012US20120077861 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same
03/29/2012US20120077859 C-substituted Diindolylmethane Compositions and Methods for the Treatment of Multiple Cancers
03/29/2012US20120077856 Pharmaceutical product
03/29/2012US20120077855 Crystalline tripeptide epoxy ketone protease inhibitors
03/29/2012US20120077851 Urea Derivatives as Kinase Inhibitors
03/29/2012US20120077850 Pirfenidone treatment for patients with atypical liver function
03/29/2012US20120077846 Treatment of renal cell carcinoma
03/29/2012US20120077845 Estrogen receptor ligands and methods of use thereof
03/29/2012US20120077843 Malignant precursor cells from ductal carcinoma in situ lesions
03/29/2012US20120077842 Quinoline derivative-containing pharmaceutical composition
03/29/2012US20120077841 Methods for cancer therapy and stem cell modulation
03/29/2012US20120077837 Anti-tumor agent
03/29/2012US20120077834 Methods of Use of Cyclopamine Analogs
03/29/2012US20120077833 Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
03/29/2012US20120077832 Besylate salt of a btk inhibitor
03/29/2012US20120077830 Caspase inhibitors and uses thereof
03/29/2012US20120077828 Chemical compounds
03/29/2012US20120077827 Zap-70 active compounds
03/29/2012US20120077826 [6,5] - bicyclic gpr119 g protein-coupled receptor agonists
03/29/2012US20120077823 Controlled release systems of pluribioactive antifungal drugs and applications thereof
03/29/2012US20120077822 In situ-formed bioactive tissue adherent films of absorbable crystallizable polymers
03/29/2012US20120077820 Compounds and method for treatment of cancer
03/29/2012US20120077819 Use of kinase inhibitor for the treatment of thymoma
03/29/2012US20120077815 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors
03/29/2012US20120077814 Sulfonamide, sulfamate, and sulfamothioate derivatives
03/29/2012US20120077811 Prodrug forms of kinase inhibitors and their use in therapy
03/29/2012US20120077810 Inhibitors Of AKT Activity
03/29/2012US20120077808 Niacin Mimetics, and Methods of Use Thereof
03/29/2012US20120077807 Niacin mimetics, and methods of use thereof
03/29/2012US20120077806 Deubiquitinase Inhibitors and Methods for Use of the Same
03/29/2012US20120077805 Unsolvated benzodiazepine compositions and methods
03/29/2012US20120077803 Uses Of NK Receptor Antagonists
1 ... 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 ... 2211